|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,175.55 INR | -0.92% |
|
-2.65% | -7.51% |
Business description: Dr. Reddy's Laboratories Limited
Number of employees: 27,811
Sales by Activity: Dr. Reddy's Laboratories Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Global Generics | 147B | 173B | 206B | 245B | 290B |
Proprietary Products | 523M | 1.61B | - | - | - |
Pharmaceutical Services and Active Ingredients (PSAI) | 38.89B | 37B | 36.65B | 29.8B | 43.24B |
Others | 2.81B | 2.87B | 3.04B | 3.91B | 2.14B |
Inter-Segment Revenues | - | - | - | - | -9.39B |
Geographical breakdown of sales: Dr. Reddy's Laboratories Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
United States | 76.7B | 80.56B | 107B | 136B | 149B |
Others | 60.95B | 68.96B | 67.47B | 72.82B | 94.4B |
India | 36.25B | 43.99B | 50.5B | 48.47B | 55.83B |
Russia | 15.82B | 20.88B | 21.23B | 22.3B | 25.96B |
Executive Committee: Dr. Reddy's Laboratories Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 59 | 2019-06-30 |
B. Phanimitra
CTO | Chief Tech/Sci/R&D Officer | - | 2023-07-31 |
K. Randhir Singh
CMP | Compliance Officer | - | 2022-03-16 |
Richa Periwal
IRC | Investor Relations Contact | 47 | - |
Kundan Kumar Jha
PRN | Corporate Officer/Principal | - | - |
Composition of the Board of Directors: Dr. Reddy's Laboratories Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 58 | 2014-05-12 | |
Gunupati Prasad
CHM | Chairman | 65 | 2013-04-01 |
Leo Puri
BRD | Director/Board Member | 65 | 2018-10-24 |
Shikha Sharma
BRD | Director/Board Member | 66 | 2019-01-30 |
| Director/Board Member | 66 | 2022-01-06 | |
Penny Wan
BRD | Director/Board Member | - | 2022-01-27 |
Arun M. Kumar
BRD | Director/Board Member | 74 | 2022-07-31 |
Claudio Albrecht
BRD | Director/Board Member | 66 | 2023-05-09 |
Alpna Seth
BRD | Director/Board Member | 63 | 2023-09-18 |
Sanjiv Mehta
BRD | Director/Board Member | 65 | 2023-12-28 |
Company details: Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd.
Door No. 8-2-337
500034, Hyderabad
+91 40 4900 2900
http://www.drreddys.com
Group companies: Dr. Reddy's Laboratories Limited
| Name | Category and Sector |
|---|---|
Dr. Reddy's Laboratories SA
 Dr. Reddy's Laboratories SA Develops, manufactures and sells pharmaceutical products | |
Dr. Reddy's Laboratories SA
Dr. Reddy's Laboratories SA Develops, manufactures and sells pharmaceutical products | |
Aurigene Oncology Ltd.
 Aurigene Oncology Ltd. BiotechnologyHealth Technology Operates as clinical stage biotechnology company |
Biotechnology
|
Aurigene Oncology Ltd.
Aurigene Oncology Ltd. BiotechnologyHealth Technology Operates as clinical stage biotechnology company |
Biotechnology
|
Aurigene Pharmaceutical Services Ltd.
 Aurigene Pharmaceutical Services Ltd. Engages in research and development of novel therapeutics for the treatment of cancer and inflammation |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.92% | -2.65% | -12.22% | +35.94% | 10.93B | |
| +1.46% | -1.53% | +38.24% | +192.75% | 925B | |
| -0.53% | +6.89% | +47.85% | +26.76% | 529B | |
| -0.18% | -2.44% | +23.61% | +40.49% | 383B | |
| +0.93% | +2.38% | +29.90% | +18.43% | 368B | |
| +0.19% | +9,784.64% | +12,858.32% | +11,934.94% | 291B | |
| +0.98% | +1.37% | +27.61% | +34.08% | 274B | |
| -1.39% | -0.86% | +8.82% | -0.79% | 275B | |
| +6.49% | +1.95% | -35.37% | -18.36% | 252B | |
| +0.33% | +1.45% | +22.79% | +22.80% | 178B | |
| Average | +0.56% | -0.59% | +1,300.95% | +1,228.70% | 348.57B | |
| Weighted average by Cap. | +0.67% | -0.58% | +1,099.08% | +1,061.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DRREDDY Stock
- Company Dr. Reddy's Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
